Tests a topical cannabidiol roll-on for migraine attacks
Tests a cannabidiol roll-on on the skin in adults with migraine.
Plain-language title generated from the registry record
Registry title: Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks
Key facts
- Where
- Tehran, IranSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 55 with migraine for at least one year, having 2-8 attacks a month. They would use Canvert-M, a roll-on with cannabidiol, during attacks.
- Age
- 18 to 55 years
- Sex
- Men and women
- Disease stage
- Migraine diagnosed by ICHD-3 criteria for at least one year, with 2-8 attacks per month. Migraine began before age 50.
- Earlier treatment
- If a person takes migraine preventive medicine, the dose must have been stable for the 2 months before screening and stay stable during the study. No migraine attack medicine within 48 hours before using Canvert-M.
Main reasons for not taking part
- Other headache disorders, such as cluster or tension headache
- Chronic migraine, or migraine that does not respond to treatment
- Allergy to menthol, lavender, rosemary, eucalyptus, wintergreen or basil oil
- Skin lesions where the product is used
- Pregnant or nursing women, or women planning pregnancy
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07093138, who can take part
Where in Iran
- Tehran Province, Tehran, Imam Khomeini Street (RA) - Before Hassan Abad SquareTehran, IranContact: Mansoureh ToghaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Alasht Pharmed
- Trial code
- NCT07093138
- Record updated
- 30 July 2025
- Original description
Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. This phase IV, single-arm, open-label clinical trial evaluated the efficacy and safety of Canvert-M in males and females aged 18 to 55 years diagnosed with migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), for the treatment of migraine attacks.Read full original descriptionShow less
Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks
Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. This phase IV, single-arm, open-label clinical trial evaluated the efficacy and safety of Canvert-M in males and females aged 18 to 55 years diagnosed with migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), for the treatment of migraine attacks.
The primary objective was to assess the reduction in headache intensity using a 4-point scale (0=no headache, 1=mild headache, 2=moderate headache, 3=severe headache).
Secondary objectives included evaluating additional efficacy and safety outcomes of Canvert-M in managing migraine attacks.
Inclusion: Males and females with age of 18 to 55 years; Age of migraine onset ˂ 50 years; Having a diagnosis of migraine according to the International Classification of Headache Disorders 3rd edition (ICHD-3) for at least one year; Having a history of 2-8 attacks per month; Remaining stable on prophylactic medication (if used) during the 2 months prior to screening and throughout the study period; Using effective contraception by the women of childbearing potential during the study; Ability to provide written, informed consent and to be compliant with the schedule of protocol assessments.
Exclusion: Receiving any abortive medication for the treatment of migraine within 48 hours before using Canvert-M; Treatment with any investigational agent within 30 days prior to screening; Having a diagnosis of other primary (cluster and tension) and secondary headache disorders; Having a history of chronic migraine headache; History of resistant or refractory migraine headaches based on European Headache Federation consensus; History of psychiatric and neurologic disorders (except migraine) or any medical comorbid conditions that interfere with the study results; History of nasal sensitivity or allergy to menthol, lavender, rosemary, eucalyptus, wintergreen and basil oil; History of substance use disorders; The presence of any skin lesions in the areas where the product is used; Nursing mothers, pregnant women, and women who plan to become pregnant during the study period; Taking carbamazepine, cilostazol, citalopram, clarithromycin, clobazam, colchicine, cyclosporine, digoxin, itraconazole, phenobarbital, phenytoin, rifampin, sirolimus, tacrolimus, tizanidine, and warfarin within 14 days of the study procedure.